Acute lung injury (ALI) is a life-threatening condition in critically unhealthy patients. In acute lung injury disorder, acute inflammation occurs in the lung, which leads to the disruption of the lung endothelial and epithelial barriers. The alveolar-capillary membrane is composed of the microvascular endothelium, interstitium, and alveolar epithelium. Acute Lung Injury Market is diagnosed clinically based on the appearance of non-cardiogenic pulmonary odema and respiratory failure in a critically ill patient. Its incidence is normal; it is likely to exist outside the intensive care setting and therefore is a condition relevant to all clinicians.
The report offers insights and in-depth analysis of the acute lung injury market, emphasizing various parameters such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players worldwide. It also includes the impact of the COVID-19 pandemic on the market across all the regions. The COVID-19 pandemic has disrupted the socioeconomic conditions of various countries across the world. Presently, the US is the world's worst-affected country due to the COVID-19 outbreak with the highest number of confirmed cases and deaths, as per the recent WHO statistics. The high number of COVID cases has negatively impacted the country's and region's economies. There has been a decline in overall business activities and growth of various industries operating in the region.
However, acute lung injury market players are initiating clinical trials to develop drugs to treat acute lung injury. For instance, Chimerix, a biopharmaceutical company, initiated a Phase II/III clinical trial in June 2020 to evaluate the safety and efficacy of Dociparstat sodium (DSTAT) in patients with acute lung injury (ALI) due to COVID-19. Furthermore, Altasciences is pleased to support ReAlta Life Sciences by conducting a Phase I trial to evaluate RLS-0071 for acute lung injury (ALI) as a result of viral infections such as COVID-19, respiratory syncytial virus (RSV), and influenza. COVID-19-related issues have propelled the acute lung injury market growth in the region.
Based on region, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America.
The high prevalence of respiratory conditions is associated with the decrease in the size of the upper airway lumen in the aging population. Lung disorders are among the most common medical conditions across the world. According to the Centers for Disease Control and Prevention (CDC), lung diseases such as chronic obstructive pulmonary disease (COPD) and acute lung injury (ALI) are the third leading cause of death in the US. People worldwide suffer from various sorts of respiratory diseases. Smoking, infections, and genetic factors are among the common factors responsible for respiratory disorders. Medical conditions such as COPD, asthma, chronic bronchitis, cystic fibrosis, and lung cancer are significant public health burdens.
Patients suffering from these respiratory disorders commonly experience difficulty in breathing. The respiratory failure associated with acute lung injury or the acute respiratory distress syndrome (ARDS) is one of the most critical contributors to postoperative mortality.
Moreover, the CDC, the US Food and Drug Administration (FDA), state and local health departments, and other clinical and public health associates continue to monitor smoking e-cigarette or vaping product use associated lung injury (EVALI). According to the CDC, a total of 2,807 hospitalized EVALI cases or deaths from all 50 states, the District of Columbia, and two US territories (Puerto Rico and US Virgin Islands) have been recorded as of February 2020. Thus, all the factors mentioned above are expected to result in the growth of the acute lung injury market during the forecast period.
Based on therapy, the acute lung injury market is segmented into mechanical ventilation, fluid management, pharmacotherapy, and adjunctive procedures. In 2021, the mechanical ventilation segment accounted for the largest market share in the global acute lung injury market. The segment's growth is attributed to the fact that mechanical ventilation in acute lung injury (ALI) aims to maintain oxygen while avoiding its toxicity and complications associated with the ventilation.
Based on end user, the acute lung injury market is segmented into hospitals, ambulatory surgery centers, and others. The hospitals segment held the largest share of the market in 2021, and the same segment is anticipated to register the highest CAGR of 4.9% of the market during the forecast period.
The acute lung injury market players adopt organic strategies such as product launch and expansion to expand their footprint and product portfolio worldwide and meet the growing demand.
The regional trends and factors influencing the Acute Lung Injury Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Acute Lung Injury Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 539.61 Million |
| Market Size by 2028 | US$ 741.98 Million |
| Global CAGR (2021 - 2028) | 4.7% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Therapy
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Acute Lung Injury Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Acute Lung Injury Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The List of Companies - Acute Lung Injury Market
The acute lung injury market majorly consists of players like GlaxoSmithKline plc., Stemedica Cell Technologies, Inc, Histocell, APEPTICO Forschung und Entwicklung GmbH, Windtree Therapeutics, Inc., ReAlta Life Sciences, Inc., Apeiron Biologics AG, Qx Therapeutics, Inc., Angion, and Asklepion Pharmaceuticals, LLC. among others. Histocell and APEPTICO Forschung und Entwicklung GmbH are the top most two companies in the market.
The growth of the market is attributed to increasing prevalence of respiratory diseases, and rising geriatric population drive the market growth. However, high cost of therapies hampers the market growth.
Asia Pacific is expected to be the fastest growing region and potential market for acute lung injury. Asia Pacific is expected to expand at a high growth rate. The growth of the acute lung injury market in this region is primarily due to high prevalence of this disease, and the rise in healthcare awareness related to the disease diagnosis. Additionally, developing healthcare infrastructure and increasing investments to boost the manufacturing capacities are projected to drive the Asia Pacific acute lung injury market during the forecast period.